Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Devices

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Revenue projections:

Revenue projections for BSX
Revenue projections for BSX

With BSX's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio 0.000000
forwardPE 15.182026
debtToEquity 48.921000
earningsGrowth 1.000000
revenueGrowth 0.116000
grossMargins 0.686330
operatingMargins 0.215450
trailingEps 2.390000
forwardEps 3.764320

BSX's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
BSX's positive earnings and revenue growth indicate that the company is well-positioned for business expansion. This growth suggests a strong financial trajectory, with BSX expected to continue increasing its profits and revenue in the coming periods.
BSX's positive gross and operating margins highlight its profitability and operational efficiency. These strong margins demonstrate the company's ability to control costs while generating substantial revenue, contributing to a healthy financial performance.
BSX's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that BSX is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for BSX
Price projections for BSX

The current price of BSX, in relation to its projections, presents a neutral outlook. There are no discernible risks or opportunities at this stage, indicating that investors may need to await further developments to make informed decisions regarding their positions in the stock.

Insider Transactions:

Insider Transactions for BSX
Insider Transactions for BSX


Recent trading of Boston Scientific Corporation stock saw 25 sales, with market price at 102.09920043945313 per share.No sell transactions were carried out during the period under review.With more buying than selling around BSX's current price, investors could be expressing optimism. This trend may suggest that the market expects favorable outcomes for the stock, leading to an increased demand at these levels.

Recommendation changes over time:

Recommendations trend for BSX
Recommendations trend for BSX


Analysts have shown a buy bias for BSX, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to BSX, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.